TG Therapeutics announces orphan drug designation for TGR-1202 for treatment of CLL
TG Therapeutics announced the FDA has granted orphan drug designation for the Company's oral, next generation PI3K Delta inhibitor, TGR-1202, for treatment of patients with chronic lymphocytic leukemia. TGR-1202 is currently being evaluated in the UNITY-CLL Phase 3 Trial for patients with CLL. August 24, 2016